1/2

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…

1 month ago

New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk

MELBOURNE, Australia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of access management solutions for healthcare and other mission-critical…

2 months ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

4 months ago